..Author: Ben Eversfield

Smaller, smarter antibody-like drugs: An update report from NDF Research

 

 

NDF Research has published a comprehensive update report on AdAlta (ASX: 1AD) outlining not only the 10 reasons to consider AdAlta (shown above) but also “Why AdAlta’s i-body can be the Next Big Scaffold” and that “AdAlta can potentially go one better than Ablynx”, who were acquired by Sanofi for US$4.8 billion in January 2018. The update report can be found here.

Publication of the report by NDF Research follows the announcement of AdAlta’s second generation lead candidate, AD-214, an Fc-fusion version of AD-114 that has an increased half-life and enhanced activity. AdAlta is currently advancing AD-214 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis. More information on AD-214 can be found here.

 

This report has been commissioned and paid for by AdAlta (the Company) and has been prepared by NDF Research, an Authorised Representative of BR Securities Australia Pty Ltd. The report solely reflects the views of NDF Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of NDF Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

 

 

 

AdAlta’s lead program, AD-214, profiled by Clinical Leader

Clinical Leader, a publication dedicated to streamlining clinical trials, has recently profiled the introduction of AD-214, AdAlta’s second generation lead candidate, with improve therapeutic and commercial potential. The article discusses the decision to delay the clinical trial by 12 months, the factors involved in the decision and suggests that “while this postponement could be painful for the company in the short run, the longer-term outcome will be a superior drug candidate for AdAlta, its partners, and patients”.

The article, titled ‘What Would Convince You To Delay Your Trial For 12 Months?‘ can be accessed here.

AdAlta IPF Program featured in Small Caps

Small Caps, a site dedicated to market news & information on ASX listed small cap companies, recently published a great feature detailing AdAlta’s recent manufacturing announcement along with background on AdAlta’s i-body technology and lead candidate, AD-214 for Idiopathic Pulmonary Fibrosis. The article, titled ‘AdAlta courts big pharma with ‘enhanced’ anti-fibrosis drug, locks-in manufacturing agreements‘ can be accessed here.

CEO Sam Cobb profiled by Fairfax Media ‘Watch out CSL, here we come’

AdAlta CEO Sam Cobb was recently profiled by Fairfax media, discussing the success story of CSL as an inspiration for AdAlta to follow in its footsteps. Click here to read the article published in the Sydney Morning Herald titled ‘Watch out CSL, here we come’: biotech gears to go global.

“My vision for AdAlta is that we become a bigger company … [with] drug discovery that’s competitive on a world scale.”

 

CEO Sam Cobb presents to the Morgans Network

AdAlta Chief Executive Officer Sam Cobb presented to the Morgans network in May 2018, providing an update on the company’s lead drug treatment AD-214 and an overview of the market opportunities for Idiopathic Pulmonary Fibrosis (IPF).

CEO Sam Cobb presents at Gold Coast Investment Showcase

AdAlta CEO Sam Cobb attended the Gold Coast Investment Showcase held on June 21-22, 2018. The showcase provides the opportunity for prospective investors to get up close and personal with some of the most exciting and innovative companies in Australia. This included biotechnology companies such as AdAlta, along with companies from the resources and technology sectors.

A recording of the presentation from the Gold Coast Investment Showcase can be viewed below, in which CEO Sam Cobb provides an overview of AdAlta including lead candidate, AD-214, which is being advanced for idiopathic pulmonary fibrosis, an indication with early transaction potential.

The significant achievements for AdAlta in 2017/18 along with expected news flow for the year ahead are also detailed in the presentation and our recent Shareholder Update.

If you would like to keep up on date on AdAlta’s progress, become a subscriber here.

AdAlta Shareholder Update June 2018

AdAlta is pleased to share with you our June 2018 Shareholder Update. AdAlta has already had a very exciting 2018; announcing its second generation lead candidate, AD-214, as well as its manufacturing partners to take AD-214 through preclinical development and into the clinic in 2020.

AdAlta is looking forward to progressing AD-214 with improved therapeutic and commercial potential, if you would like to keep up to date with progress, sign up to be an AdAlta subscriber here.

 

AdAlta to advance improved lung fibrosis therapy, AD-214

  • AdAlta’s lead drug for treatment of Idiopathic Pulmonary (lung) Fibrosis AD-114 redesigned as new molecule, called AD-214
  • AD-214 retains unique therapeutic benefits of AD-114, but with greater potency and significantly improved half-life
  • New design combines the i-body with an Fc fragment that enables the drug to stay in the body for longer, benefitting patients

 

 

Australian biotech AdAlta (ASX: 1AD) today announced major improvements to the design of its preclinical i-body therapy for lung fibrosis, AD-114, which has significantly enhanced the drug’s potency and extended its half-life.

AdAlta has called its improved AD-114 molecule AD-214.

AD-214 contains two AD-114 i-body molecules at its front end, to increase its ability to bind to its human target, CXCR4, where it exerts its therapeutic effect. The addition of the Fc fragment (the tail region of a traditional monoclonal antibody) extends AD-214’s half-life, or duration of time in which it will stay in the body.

AdAlta CEO Sam Cobb said the Company will progress AD-214 into a Phase I clinical trial in the second half of 2019. Accordingly, the Company will prioritize development of AD-214 and halt further expenditure on manufacturing the current AD-114 molecule.

“AD-214 will ultimately be of greater benefit to future patients and potential commercial partners,” Cobb said.

“An increased half-life results in significantly less frequent dosing and therefore a more desirable and acceptable outcome for patients leading to greater drug compliance.  Less frequent dosing is considered important for patients and their physicians when treating fibrotic diseases.

“AD-214 will widen the commercial interest when we progress our partnering discussions.  Although the redesign of AD-114 into the new Fc-Fusion molecule AD-214 delays us from entering human clinical trials by around 12 months, AdAlta believes the timeline associated with this new molecule is more than offset by its broader clinical utility in a wider range of fibrotic diseases outside of Idiopathic Pulmonary Fibrosis”.

Dr Robert Peach, AdAlta’s Non-Executive Director who has a long history in the development of commercially available biologic drugs, including the Fc-Fusion drug blockbuster Orencia commented, “The data on AdAlta’s CXCR4 i-body antagonist is extremely encouraging for the treatment of multiple fibrotic diseases, including NASH, and age related macular degeneration.

“We have been able to leverage all the work done to date on AD-114 in the development of AD-214.  This means we can make use of our existing strong data package and retain orphan drug status for treatment of idiopathic pulmonary fibrosis.  We expect AD-214 will deliver increased commercial and therapeutic benefits in multiple fibrotic conditions, combined with the strong commercial precedent of existing mainstream drugs developed using the Fc-Fusion route reinforces the validity of this approach.”

There are greater than 70 antibodies currently on the market and eleven FDA approved Fc-Fusion proteins. There is a straightforward method of manufacturing and consequently it is expected that costs of goods can be reduced for AD-214 due to less frequent dosing and a well understood manufacturing pathway.

Learn more about AD-214 here, check out AdAlta’s latest company presentation and listen to an interview with CEO Sam Cobb.

AdAlta will also be holding Shareholder Briefing Sessions in Melbourne, Brisbane, Perth and Sydney in April, find out more information here.